生物信息学分析TLCD1在肝细胞肝癌中的表达及意义

Bioinformatics Analysis of the Expression and Significance of TLCD1 in Hepatocellular Carcinoma

目的基于生物信息学分析TLCD1在肝细胞肝癌(HCC)表达及临床价值。方法通过TIMER2.0、GEPIA和UALCAN数据库分析TLCD1mRNA在HCC组织和正常组织中的表达差异。使用UALCAN数据库中进一步分析TLCD1mRNA与HCC临床病理参数的关系。采用Kaplan-MeierPlotter数据库和GEPIA数据库分析TLCD1mRNA表达高低对HCC患者预后的影响。通过LinkedOmics数据库探讨HCC中TLCD1的共表达基因,并进行通路分析。结果TLCD1mRNA在HCC组织中表达高于正常组织,且TLCD1mRNA在亚洲人、TP53突变、低分化或未分化的HCC组织中表达水平较高(P<0.05)。生存分析提示,TLCD1mRNA高表达的HCC患者总生存期、无复发生存期、无进展生存期、疾病特异性生存期、无病生存期均较差(P<0.05)。共表达分析显示,TLCD1可能与核糖体、氧化磷酸化、剪切体、蛋白酶体、RNA转运、嘌呤代谢等信号通路相关。结论在HCC组织中TLCD1mRNA表达增高,且TLCD1高表达的HCC患者预后较差,可能成为HCC新的治疗靶点。

Objective To analyze the expression and clinical value of TLCD1 in hepatocellular carcinoma(HCC)based on bioinformatics.Methods The expression of TLCD1mRNA in HCC tissues and normal tissues was analyzed by TIMER2.0,GEPIA and UALCAN databases.The relationship between TLCD1 mRNA and clinicopathological parameters of HCC was further analyzed using the UALCAN database.Kaplan-MeierPlotter database and GEPIA database were used to analyze the effect of TLCD1 mRNA expression on the prognosis of HCC patients.The co-expressed genes of TLCD1 in HCC were explored by LinkedOmics database,and pathway analysis was performed.Results The expression of TLCD1 mRNA in HCC tissues was higher than that in normal tissues,and the expression level of TLCD1 mRNA was higher in Asian,TP53 mutant,poorly differentiated or undifferentiated HCC tissues(P<0.05).Survival analysis showed that the overall survival,recurrence-free survival,progression-free survival,disease-specific survival and disease-free survival of HCC patients with high expression of TLCD1 mRNA were poor(P<0.05).Co-expression analysis showed that TLCD1 may be related to ribosome,oxidative phosphorylation,spliceosome,proteasome,RNA transport,purine metabolism and other signaling pathways.Conclusion In HCC tissues the expression of TLCD1 mRNA is increased,and the prognosis of HCC patients with high expression of TLCD1 is poor,which may become a new therapeutic target for HCC.